… therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company … October 21, 2025 Company management will participate in an RNA Editing panel at 1:00 p.m. ET and will conduct 1x1 …
… RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the … the scientific community’s understanding of ADAR-mediated RNA-editing mechanisms and their therapeutic potential. As …
… Application (CTA) advancing ProQR’s Axiomer™ ADAR-mediated RNA editing platform into clinical development LEIDEN, … RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the …
… against a key Axiomer patent protecting ADAR-mediated RNA editing Well-capitalized with €139 M, in cash and cash … defense of a key Axiomer patent protecting ADAR-mediated RNA editing. The oppositions were filed in February 2021 with …
… to focus on accelerating the development of Axiomer ® RNA base-editing technology platform across multiple … Agency (EMA) and US Food and Drug Administration (FDA) RNA editing technology – Accelerate development of the …
… RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual … Axiomer platform, the therapeutic potential of our Axiomer RNA editing oligonucleotides, and the potential of our …